en Radiation Biology Radiation Biology گزارش کوتاه Short Report <div style="text-align: justify;"><span style="font-size:10pt"><span style="text-justify:newspaper"><span style="text-kashida-space:50%"><span style="line-height:119%"><span style="font-family:Calibri"><span style="color:black"><span lang="en-US" style="font-size:9.0pt"><span style="font-family:Calibri"><span style="color:#1f497d"><span style="font-style:italic"><span style="font-weight:bold"><span style="language:en-US">Background:</span></span></span></span></span></span> <span lang="en-GB" style="font-size:9.0pt"><span style="font-family:Calibri"><span style="color:black"><span style="language:en-GB">This study compares treatment plans for gastric cancer patients generated using the Varian IX linear accelerator (linac) and the uRT-Linac 506C. </span></span></span></span><span lang="en-GB" style="font-size:9.0pt"><span style="font-family:Calibri"><span style="color:#1f497d"><span style="font-style:italic"><span style="font-weight:bold"><span style="language:en-GB">Materials and Methods: </span></span></span></span></span></span><span lang="en-GB" style="font-size:9.0pt"><span style="font-family:Calibri"><span style="color:black"><span style="language:en-GB">A retrospective analysis was performed on ten gastric cancer patients. Treatment plans were initially created using Varian Eclipse v13.5 treatment planning system (TPS) and uRT-TPS for intensity-modulated radiation therapy (IMRT), respectively; all plans were developed by an experienced physicist and determined to be clinically acceptable. Dosimetric parameters were compared for the planning target volume (PTV) and organs at risk (OARs), including the conformity index (CI), homogeneity index (HI), and monitor unit (MU) efficiency. The delivery accuracy of both accelerator systems was assessed using gamma index analysis. </span></span></span></span><span lang="en-GB" style="font-size:9.0pt"><span style="font-family:Calibri"><span style="color:#1f497d"><span style="font-style:italic"><span style="font-weight:bold"><span style="language:en-GB">Results: </span></span></span></span></span></span><span lang="en-GB" style="font-size:9.0pt"><span style="font-family:Calibri"><span style="color:black"><span style="language:en-GB">Results indicated that the uRT-Linac 506C provided superior dose conformity and target volume coverage compared to the Varian IX linac, as evidenced by a higher V45/% parameter for the uRT-Linac 506C. For the left kidney, the Varian IX linac had a significantly lower maximum dose (Dmax); however, its mean dose (Dmean), V10, and V20 were significantly higher than those of the uRT-Linac 506C. Similar trends were observed for the right kidney and liver, where the Varian IX linac exhibited significantly higher doses and volumes for specific parameters. </span></span></span></span><span lang="en-GB" style="font-size:9.0pt"><span style="font-family:Calibri"><span style="color:#1f497d"><span style="font-style:italic"><span style="font-weight:bold"><span style="language:en-GB">Conclusion: </span></span></span></span></span></span><span lang="en-GB" style="font-size:9.0pt"><span style="font-family:Calibri"><span style="color:black"><span style="language:en-GB">In conclusion, both linacs can achieve clinical requirements for gastric cancer radiotherapy; however, the uRT-Linac 506C demonstrated improved dose conformity and target coverage in this study. Further research is warranted to validate these findings and investigate potential clinical implications.</span></span></span></span></span></span></span></span></span></span></div> Gastric cancer, intensity modulated radiotherapy, treatment plans, dosimetric parameters. 283 287 http://ijrr.com/browse.php?a_code=A-10-1-1488&slc_lang=en&sid=1 Y. Tian 7900319475328460033030 7900319475328460033030 No Radiotherapy Center, Hubei Key Laboratory of Tumor Biological Behaviors, Hubei Cancer Clinical Study Center, Zhongnan Hospital of Wuhan University, Wuhan, China X. Peng 7900319475328460033031 7900319475328460033031 No Radiotherapy Center, Hubei Key Laboratory of Tumor Biological Behaviors, Hubei Cancer Clinical Study Center, Zhongnan Hospital of Wuhan University, Wuhan, China L. Yang yanglan_zn163.com 7900319475328460033032 7900319475328460033032 Yes Radiotherapy Center, Hubei Key Laboratory of Tumor Biological Behaviors, Hubei Cancer Clinical Study Center, Zhongnan Hospital of Wuhan University, Wuhan, China H. Liu hbzkznyy@163.com 7900319475328460033033 7900319475328460033033 No Radiotherapy Center, Hubei Key Laboratory of Tumor Biological Behaviors, Hubei Cancer Clinical Study Center, Zhongnan Hospital of Wuhan University, Wuhan, China